niacin has been researched along with Hemorrhage in 13 studies
Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.
vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).
nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.
Hemorrhage: Bleeding or escape of blood from a vessel.
| Excerpt | Relevance | Reference |
|---|---|---|
| " However, the trial also identified previously unrecognized serious adverse effects (including new-onset diabetes, bleeding, and infection)." | 2.90 | Serious Adverse Effects of Extended-release Niacin/Laropiprant: Results From the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) Trial. ( Armitage, J; Chen, F; Haynes, R; Hopewell, JC; Landray, MJ; Li, J; Parish, S; Valdes-Marquez, E, 2019) |
| "Niacin-laropiprant was associated with an increased incidence of disturbances in diabetes control that were considered to be serious (absolute excess as compared with placebo, 3." | 2.79 | Effects of extended-release niacin with laropiprant in high-risk patients. ( Armitage, J; Aung, T; Collins, R; Craig, M; Haynes, R; Hopewell, JC; Jiang, L; Landray, MJ; Parish, S; Tomson, J; Wallendszus, K, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (69.23) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (7.69) | 29.6817 |
| 2010's | 3 (23.08) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Haynes, R | 2 |
| Valdes-Marquez, E | 1 |
| Hopewell, JC | 2 |
| Chen, F | 1 |
| Li, J | 1 |
| Parish, S | 2 |
| Landray, MJ | 2 |
| Armitage, J | 2 |
| Aung, T | 1 |
| Tomson, J | 1 |
| Wallendszus, K | 1 |
| Craig, M | 1 |
| Jiang, L | 1 |
| Collins, R | 1 |
| McCarthy, M | 1 |
| PELUSE, S | 1 |
| LEVENSON, SM | 1 |
| GREEN, RW | 1 |
| BIANCO, T | 1 |
| VOARINO, EL | 1 |
| STURA, L | 1 |
| MANNARI, M | 1 |
| KRASSER, R | 1 |
| PLETSCHER, A | 1 |
| GORDON, DM | 1 |
| PEPLAU, G | 1 |
| Chaidemenos, GC | 1 |
| Mourellou, O | 1 |
| Karakatsanis, G | 1 |
| Koussidou, T | 1 |
| Xenidis, E | 1 |
| Charalampidou, H | 1 |
| Avgoloupis, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Trial of the Long-term Clinical Effects of Raising HDL Cholesterol With Extended Release Niacin/Laropiprant[NCT00461630] | Phase 3 | 25,673 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00461630)
Timeframe: During scheduled treatment period (median duration 3.9 years)
| Intervention | participants (Number) |
|---|---|
| ER Niacin/Laropiprant | 807 |
| Placebo | 897 |
Non-fatal myocardial infarction (MI) or coronary death (NCT00461630)
Timeframe: During scheduled treatment period (median duration 3.9 years)
| Intervention | participants (Number) |
|---|---|
| ER Niacin/Laropiprant | 668 |
| Placebo | 694 |
Non-fatal myocardial infarction or coronary death, non-fatal or fatal stroke, or revascularisation (NCT00461630)
Timeframe: During scheduled treatment period (median duration 3.9 years)
| Intervention | participants (Number) |
|---|---|
| ER Niacin/Laropiprant | 1696 |
| Placebo | 1758 |
All-cause mortality (NCT00461630)
Timeframe: During scheduled treatment period (median duration 3.9 years)
| Intervention | participants (Number) |
|---|---|
| ER Niacin/Laropiprant | 798 |
| Placebo | 732 |
Fatal or non-fatal (NCT00461630)
Timeframe: During scheduled treatment period (median duration 3.9 years)
| Intervention | participants (Number) |
|---|---|
| ER Niacin/Laropiprant | 498 |
| Placebo | 499 |
2 trials available for niacin and Hemorrhage
| Article | Year |
|---|---|
Serious Adverse Effects of Extended-release Niacin/Laropiprant: Results From the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) Trial.
Topics: Cardiovascular Diseases; Delayed-Action Preparations; Diabetes Mellitus; Double-Blind Method; Drug T | 2019 |
Effects of extended-release niacin with laropiprant in high-risk patients.
Topics: Aged; Atherosclerosis; Cholesterol, LDL; Delayed-Action Preparations; Diabetes Mellitus; Double-Blin | 2014 |
11 other studies available for niacin and Hemorrhage
| Article | Year |
|---|---|
Niacin fails to reduce vascular events in large randomised trial.
Topics: Blood Glucose; Cholesterol, HDL; Delayed-Action Preparations; Diabetes Mellitus; Drug Therapy, Combi | 2014 |
Gingival hemorrhage with oral manifestations in hereditary hemorrhagic telangiectasia; successful control with sclerosing agent sylnasol; effect of vitamin P and nicotinic acid; role in case reported which was observed 5 years.
Topics: Flavones; Gingiva; Gingival Hemorrhage; Hemorrhage; Humans; Mouth; Niacin; Nicotinic Acids; Oral Hem | 1946 |
Ascorbic acid, riboflavin, thiamin, and nicotinic acid in relation to severe injury, hemorrhage, and infection in the human.
Topics: Ascorbic Acid; Deficiency Diseases; Hemorrhage; Humans; Infections; Metabolism; Niacin; Nicotinic Ac | 1946 |
[Isonicotinic acid hydrazide and hemorrhages in tuberculosis].
Topics: Hemorrhage; Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Vascular effects of isonicotinic acid hydrazide; case reports].
Topics: Female; Hemorrhage; Humans; Isoniazid; Niacin; Nicotinic Acids; Pelvis; Tuberculosis; Tuberculosis, | 1954 |
[The effect of nicotinic acid isomers on bleeding and coagulation time].
Topics: Blood Coagulation; Blood Coagulation Tests; Capillary Permeability; Collapse Therapy; Hemorrhage; Hu | 1954 |
[Effect of isopropyl-isonicotinic acid hydrazide on the metabolism of catechol amines and 5-hydroxytryptamine in the brain].
Topics: Amines; Brain; Catechols; Epinephrine; Hemorrhage; Isoniazid; Niacin; Nicotinic Acids; Norepinephrin | 1957 |
SUDDEN LOSS OF VISION; DIAGNOSIS AND MANAGEMENT.
Topics: Adrenal Cortex Hormones; Angiomatosis; Anticoagulants; Aortic Diseases; Blindness; Carbonic Anhydras | 1964 |
[Case report on the injurious side-effects of isoniazid].
Topics: Gastrointestinal Hemorrhage; Hemorrhage; Isoniazid; Niacin; Nicotinic Acids; Stomach; Stomach Diseas | 1954 |
[Ultrasonics in ophthalmology].
Topics: Eye Diseases; Hemorrhage; Humans; Ophthalmology; Pellagra; Ultrasonic Therapy; Ultrasonics; Vitreous | 1951 |
Acute hemorrhagic pellagra in an Albanian refugee.
Topics: Acute Disease; Adult; Albania; Facial Dermatoses; Follow-Up Studies; Hand Dermatoses; Hemorrhage; Hu | 2002 |